Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
OptiNose, Inc. (OPTN)
Last optinose, inc. earnings: 3/5 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.optinose.com
Company Research
Source: GlobeNewswire
Optinose expects early April availability of XHANCE in retail pharmacies XHANCE Xperience program launched in early March YARDLEY, Pa., March 13, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2017, and provided recent operational highlights. “2017 was a transformational year for Optinose, and 2018 is poised to be even better as we make XHANCE available to the millions of patients with nasal polyps,” commented CEO Peter Miller. “The first-pass approval of XHANCE by the FDA in September 2017 is a testament to the quality of the efforts by the team in the execution of our development and regulatory strategies. Having raised $250 million in gross proceeds in 2017 to strengthen our capital position, we have now turned our team’s attention more fully to the successful launch of XHANCE. Following FDA
Show less
Read more
Impact Snapshot
Event Time:
OPTN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPTN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPTN alerts
High impacting OptiNose, Inc. news events
Weekly update
A roundup of the hottest topics
OPTN
News
- OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Optinose to Present at the Needham Virtual Healthcare ConferenceGlobeNewswire
- OptiNose, Inc. (NASDAQ: OPTN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- OptiNose, Inc. (NASDAQ: OPTN) had its price target raised by analysts at Lake Street Capital from $3.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- OptiNose granted FDA nod to expand labeling for sinusitis therapy [Seeking Alpha]Seeking Alpha
OPTN
Earnings
- 3/7/24 - Beat
OPTN
Sec Filings
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- OPTN's page on the SEC website